Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis
- 15 March 2014
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 93 (8) , 1287-1295
Abstract
We have performed a retrospective analysis of all patients with extragastric mucosa-associated lymphoid tissue (MALT) lymphoma treated at our institution to compare the efficacy of first-line therapeutic modalities including surgery, radiation, systemic therapy, and antibiotics. One hundred eighty-five patients with extragastric MALT lymphoma with a median age of 63 (interquartile range (IQR) 50–74) years and a median follow-up time of 49 (IQR 18–103) months were retrospectively analyzed. Time to progression and time to next therapy were used as surrogate endpoints for efficacy. Patients having either surgery (100 %), chemo/immunotherapy (85.5 %), or radiation (80 %) had significantly (p = 0.01) higher response rates than patients treated with antibiotics (33.3 %). Patients who were irradiated had significantly more progressive disease, but also the longest follow-up time. Stage, elevated LDH, anemia, elevated beta-2 microglobulin, plasmacytic differentiation, monoclonal gammopathy, or autoimmune disease did not influence the rate of disease progression nor did complete remission or partial remission from initial therapy influence time to and rate of progression. There was no significant difference in the median time to progression (p = 0.141), but the estimated time to progression (p = 0.023) as well as the estimated time to next therapy (p = 0.021) was significantly different among the various cohorts favoring surgery, chemo/immunotherapy, and radiation. Our results suggest extragastric MALT lymphoma as a potential systemic disease irrespective of initial stage. Radiation, surgery, and chemo/immunotherapy seem to be equally effective in achieving remissions and prolonged progression free survivals, but a curative potential is questionable. Localized MALT lymphomas affecting the thyroid gland or the lungs have excellent long-term progression-free survivals with surgical treatment only.Keywords
This publication has 32 references indexed in Scilit:
- Genomic analysis of Non‐Splenic Marginal Zone Lymphomas (MZL) indicates similarities between nodal and extranodal MZL and supports their derivation from Memory B‐cellsBritish Journal of Haematology, 2011
- EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALTGut, 2011
- Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomasJournal of Hepatology, 2008
- Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infectionArthritis Care & Research, 2007
- Most cases of primary salivary mucosa‐associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infectionBritish Journal of Haematology, 2004
- Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissueBlood, 2003
- The World Health Organization Classification of Hematological Malignancies Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997Laboratory Investigation, 2000
- Clinical Features, Treatment and Outcome in a Series of 93 Patients with Low-Grade Gastric MALT LymphomaLeukemia & Lymphoma, 1997
- The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pyloriThe Lancet, 1993
- Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pyloriThe Lancet, 1993